The ubiquitin proteasome system (UPS) has garnered much attention due to its potential for the development of therapeutics. Following a successful clinical application of general proteasome inhibitors much effort has been devoted to targeting individual UPS components including E3 enzymes and deubiquitinases that control specificity of ubiquitination. Our group has developed a novel approach for targeting the UPS proteins using engineered ubiquitin variants (Ubvs). These drug-like proteins can serve as valuable tools to study biological function of UPS components and assist in the development of small molecules for clinical use. In this review, we summarize studies of Ubvs targeting members of three major families, including deubiquitinases, HECT E3 ligases, and CRL E3 ligases. In particular, we focus on Ubv binding mechanisms, structural studies, and effects on enzyme function. Furthermore, new insights gained from the Ubvs are discussed in the context of small molecule studies. 
| I N T R O D U C T I O N
Despite extensive efforts, potent small molecules have only been developed against a small number of DUBs, and most of these inhibitors exhibit low specificity and potency. 23 Furthermore, there are no published structures of human DUBs in complex with small molecule inhibitors, and this has prevented detailed understanding of the inhibition mechanisms to guide further design.
Motivated by the paucity of effective inhibitors of DUBs, our group developed an approach to generate potent and specific Ubvs as protein-based inhibitors. 18 The Ub specific protease (USP) subfamily contains a conserved binding site for the distal Ub that is conjugated through its C-terminal moiety to lysine in other Ub or protein substrates. Based on analysis of available USP-Ub structures, we targeted for combinatorial mutagenesis approximately 30 residues on Ub that interact with the USP Ub-binding site ( Figure 2A ). Resulting libraries containing billions of Ubvs were displayed on phage and subjected to binding selections for particular DUBs and other Ub-associated proteins. This strategy was successful in generating tight and specific Ubvs binding to USP2, USP8, or USP21 (Table 1) . Additionally, this approach also generated specific Ubvs for the: DUBs OTUB1 and JAB1, members of the ovarian tumor protease (OTU) and JAB1/MPN/MOV34
(JAMM) subfamilies, respectively; E2 conjugating enzyme Cdc34;
HECT E3 ligases NEDD4 and ITCH; and the non-catalytic UBD of USP37. These results showed that the common Ub epitope that engages many Ub-associated proteins can be fine-tuned for specific targeting of particular proteins.
The structures of USP2, USP21, USP8, and OTUB1 complexes revealed that the Ubvs bound to the distal Ub-binding site and acted as inhibitors of diUb cleavage. However, the Ubv interaction mode
The ubiquitin proteasome system. The cartoon shows an overview of the ubiquitination process and the major components of the UPS. In the first step of Ub conjugation, E1 consumes ATP to form a high energy thioester bond between the Ub C-terminal carboxyl group and the E1 active site cysteine thiol group. In the next step, the activated Ub is transferred to the E2 active site cysteine. In the final step, E3 mediates conjugation of the Ub C-terminal carboxyl group to an amino group of a lysine residue in a substrate protein or another Ub molecule. In this step, the Ub is either transferred through an E3 active site cysteine (HECT E3 ligases) or directly from an E2 to the receiving lysine. DUBs catalyze the cleavage of the Ub C-terminal carboxyl from substrate proteins or from Ub chains to reverse ubiquitination. The structure of Ub (PDB: 1UBQ) is shown (top right), indicating the location of the C-terminal carboxyl conjugation site and the seven acceptor lysine residues, which are shown as red sticks. The number of members in each UPS family is indicated in parenthesis and was taken from the following studies: 1, 7 Figure 2B ,C). Notably, these
Ubvs contained only three substitutions relative to the Ub.wt, demonstrating that strengthening just a few key interactions can lead to dramatic improvements in affinity and specificity (Table 1 ). In the case of OTUB1, although the Ubv bound in a similar orientation, it was slightly rotated relative to Ub.wt ( Figure 2E ). However, still only a small number of substitutions relative to Ub.wt were sufficient to generate high affinity and specificity ( and USP21, respectively. 25 The Ub is shown as surface and the residues of the identified core functional epitope are labeled and colored red or yellow if they were the same or different, respectively, in Ubv.2 and Ubv.21
GORELIK AND SIDHU | 33 and Ubv.21, and these were involved in conserved interactions between the Ubvs and USPs. In contrast, the three residues that differed in Ubv.2 or Ubv.21 relative to Ub.wt clustered together and mediated different interactions with USPs that could be exploited to generate high specificity inhibitors ( Figure 2F ). Similar analyses could be extended to dissect other Ub interactions with diverse members of the UPS and should prove useful for structure-guided design of specific inhibitors.
Others have also generated Ubv inhibitors of other USPs. 27, 28 In contrast to our approach which targeted surface exposed Ub residues involved in USP binding, these studies randomized computationally selected residues predicted to affect the conformation of the b1-b2
loop that interacts with USPs. Phage display was used to generate Ubvs with submicromolar affinities for USP14 and reduced affinities for the UCH DUB subfamily. 27 NMR analysis demonstrated that substitutions in these Ubvs do not cause detectable changes in the b1-b2
loop conformational state, but rather, slow down its conformational motions, which highlights the importance of conformational dynamics for Ub interactions. The Ubv library designed to alter the b1-b2 loop conformation was also used to generate binders to USP7 and affinity was further improved with additional surface mutations. 28 The Ubv inhibited catalytic activity, but the structure of the Ubv-USP7 complex was not solved, preventing characterization of the binding mechanism.
These results further highlight the amenability of the Ub scaffold for generation of Ubvs targeting the DUB family.
In summary, tight and specific Ubv inhibitors have been generated against several DUBs and have been shown to be useful tools for exploring molecular details of DUB interactions and for investigating 
| M O D U LA T O R S O F H E C T E L I G A S E S
Of the 600 E3 ligases encoded by the human genome, 28 belong to the extensively characterized HECT family, and these contribute to many essential cell processes and have been linked to numerous diseases. 30 HECT family members share a conserved C-terminal catalytic HECT domain that is composed of the flexibly tethered N-lobe and Clobe. The N-lobe binds to an E2 enzyme charged with Ub, while the Clobe receives the Ub transferred from the E2 enzyme ( Figure 3A ). In in the case of ITCH, 33 or both in the case of WWP1 and WWP2. 34, 35 In addition to the C-lobe active site that interacts with Ub, members of the NEDD4 family also contain a weak Ub-binding N-lobe exosite. 36 Several studies suggested that binding of the substrate-linked Ub to the N-lobe exosite enhances polyubiquitination by orienting the distal end of growing polyubiquitin chains [37] [38] [39] and by enhancing the processive ubiquitination mode. 40 Additionally, the N-lobe exosite was shown to directly overlap with the C2 binding surface on SMURF2 and NEDD4, suggesting that Ub binding to this site might also contribute to relieving C2 mediated autoinhibition. 41 To date only a handful of small molecules targeting HECT E3
ligases have been reported, including a general HECT inhibitor 42 and an ITCH inhibitor that target active sites, 43 a SMURF inhibitor that disrupts substrate binding, 44 and a NEDD4 inhibitor that binds the N-lobe exosite and inhibits processive ubiquitination. 40 While these small molecules provide some insight into different mechanisms that can modulate HECT function, the small number of available molecules, lack of structural information (a structure is only available for the NEDD4 inhibitor), and lack of potency and specificity in some cases suggest that alternative methods are required to systematically investigate the mechanisms and biological outcomes of specifically targeting HECT E3 ligases across the whole family.
We used the phage-displayed Ubv library ( Figure 2A ) to target HECT domains from 19 human proteins (including all members of the NEDD4 family) and from Rsp5, the yeast homologue of human NEDD4. 18, 45 These selections yielded a total of 69 unique Ubvs, which displayed high affinity and specificity for their targets, although some cross-reactivity was observed for closely related homologs ( Table 2 ).
The Ubvs acted as inhibitors, activators or modulators of ubiquitination 45 . Effect on the cell migration of HCT116 cells is indicated for Ubvs shown to influence cell migration in a lentiviral screen with pooled Ubvs. 45 N-lobe exosite not only relieves autoinhibition but also allosterically activates the enzyme. Allosteric activation by Ub binding was observed in other studies for an E2 19 and RING E3 ligases, 21 but the above result was the first demonstration that HECT E3 ligases can also be allosterically activated through the N-lobe exosite.
Since the N-lobe exosite was previously implicated in binding (Table 2) . Interestingly, despite the modulatory effect of Ubv.NL.1 on NEDD4L autoubiquitination observed in vitro, Ubv.NL1.1 expression had an overall activating effect on NEDD4L function in cells (Table 2) . Additionally, all Ubvs generated against HECT3 ligases were pooled and screened for their effects on cell migration. This screen identified several Ubvs whose targets (HACE1, SMURF2, and WWP1/2) were known to be involved in cell migration and which affected cell migration in accordance to their in vitro properties ( Table 2 ). The screen also recovered Ubv.NL.1 targeting NEDD4L as a strong inhibitor of cell migration, identifying NEDD4L as a novel regulator of this process (Table 2 ).
In 
| I N H IB I T O RS O F S C F E3 L I G A S E S
The SCF family of E3 ligases is one of the largest and best characterized of the CRL families ( Figure 1 ). The SCF complex is composed of the invariant RBX1, CUL1, and SKP1 subunits, and one of the 69 F-box proteins that determine substrate specificity ( Figure 4A ). The cullin protein CUL1 brings together the RING protein RBX1, which recruits the E2 enzyme, and the adaptor SKP1 in complex with the F-box protein, which recruits substrate. All F-box proteins are defined by the presence of a small F-box domain that interacts with SKP1. The family is further subdivided according to the nature of the substrate-binding domain including WD40, LRR and "other domains," which are referred to as the FBW, FBL, and FBO subfamilies, respectively ( Figure 4A ). Numerous F-box proteins control essential cell processes including cell cycle, DNA repair and apoptosis. 57 Consequently, many F-box proteins are attractive targets for treatment of cancer and other diseases. However, only a few F-box proteins have been targeted with small molecules, with the majority of the effort devoted to SKP2, which drives cell cycle progression and is the best validated cancer target within the family ( Figure 4B ). Most reported inhibitors function by disrupting the interaction between an F-box protein and its substrate. Additionally, inhibitors that disrupt the interaction of an F-box domain with SKP1 were generated for SKP2 and the yeast protein Met30 ( Figure 4B ).
To gauge the potential of targeting F-box proteins with Ubvs, we used the phage-displayed Ubv library (Figure 2A ) against the wellcharacterized F-box protein FBW7 in complex with SKP1. 56 Unlike
DUBs and HECT E3 ligases, Ub-binding sites have not been characterized on most F-box proteins, the exception being FBW family members which interact with Ub through the WD40 substrate-binding domain that is thought to control auto-ubiquitination. 58 Unexpectedly, an Ubv (Fw7.1) generated against FBW7 in complex with SKP1 did not target its WD40 domain, but instead bound at the interface of the SKP1 protein and the F-box domain ( Figure 4C ). Remarkably, the binding surface of Ubv.Fw7.1 overlapped almost exactly with the binding surface of CUL1 ( Figure 4D ), and consequently, the Ubv inhibited SCF Fbw7 activity by disrupting CUL1 binding. Thus, the Ubv-phage screen identified a previously uncharacterized inhibitory site in the SCF E3 ligases defined by the interface of SKP1 and the F-box domain. Since all members of the family contain an F-box domain, in principle the whole F-box family could be inhibited in a systematic manner by targeting this site.
To generate specific Ubv inhibitors against different F-box proteins, we developed a next-generation Ubv library tailored to target the SKP1-F-box interface. Characterization of the binding specificity of Ubv.Fw7.5 (affinity matured version of Ubv.Fw7.1) revealed that while it displayed the strongest binding to its target, it also bound to several related F-box proteins in complex with SKP1 (Table 3 ). The observed cross-reactivity was explained by the mechanism of Ubv binding Table   3 ). The Ubvs generated against FBW7 and FBW11 were tested in cells and, consistent with their in vitro properties, disrupted the interactions of their cognate F-box targets with CUL1 and inhibited degradation of known F-box substrates (Table 3) .
Ubvs generated against F-box proteins show that members of this family can be inhibited in a systematic manner by targeting the CUL1-binding surface on the SKP1-F-box complex and that highly specific Ubvs can be obtained. This inhibitory site was not previously discovered by small molecule studies and offers several advantages ( Figure   4B ). The whole F-box family can be targeted in a systematic manner by this approach without prior knowledge of the F-box-substrate interactions, which are poorly characterized in most cases. Additionally, the SKP1-F-box domain complexes are easily purified and amenable to structural studies, thus facilitating the search for inhibitors. Interestingly, CUL1 was found to have extremely high affinity in vitro for the SKP1-F-box complex 56, 59 and this may have prevented the identification of small molecules inhibitors that disrupt CUL1 binding by previous studies. However, despite very tight binding of CUL1 observed in vitro, Ubvs were still able to disrupt SKP1-F-box interaction with CUL1 in cells, most likely due to the action of exchange factor CAND1 that promotes dissociation of CUL1 in cells. 59 This suggests that small molecule inhibitors of CUL1 binding could potentially be identified through in vitro assays that screen for the displacement of
Ubvs from SKP1-F-box complexes. We anticipate that specific Ubv inhibitors targeting the SKP1-F-box interface can be generated against a significant proportion of the F-box family and would provide valuable tools for validation of therapeutic targets and assist in development of inhibitory small molecules.
| I N H IB I T O RS O F AP C /C
The APC/C complex contains at least 15 different core subunits and is the most elaborate of the CRL E3 ligases. 60 The organization of the catalytic core resembles that of the SCF E3 ligases, as it contains the cullin subunit APC2, the RING protein APC11, the adaptor protein APC10, and two interchangeable substrate binding subunits CDC20
and CDH1. APC/C plays a central role during cell cycle, where APC/ C CDC20 is responsible for driving the anaphase transition and mitotic exit, while APC/C CDH1 is mainly involved in governing transition through the G1 phase. 61 Considering the central role of APC/C in cell cycle progression, it represents an attractive target for cancer therapy especially in the case of the APC/C CDC20 complex that is required for mitotic exit. 62 To date, two small molecule inhibitors that either block CDC20 and CDH1 interaction with APC/C 63 or disrupt substrate binding to CDC20 64 have been generated, and they provide some insight into the mechanisms and outcomes of APC/C inhibition. However,
given the central role of the APC/C complex in cell biology and its immense complexity, development of additional reagents would be highly beneficial for investigating APC/C function and assessing the consequences of targeting different sites.
Phage-displayed libraries ( Figure 2A ) were used to generate Ubvs targeting APC11, the RING subunit of APC/C (Table 3) . 65 APC11 contains an Ub-binding exosite, which presumably serves to capture substrate-linked Ub in proximity to the E2 active site and contributes to chain elongation mediated by the UBE2S E2 enzyme. 66 Analysis of the APC11-Ubv complex coupled with NMR and enzyme assays demonstrated that the Ubv binds through the same interface and targets the same surface on APC11 as Ub.wt ( Figure 4E ). Accordingly, the Ubv impeded in vitro multiubiquitination mediated by the UBE2C E2 enzyme and chain elongation mediated by the UBE2S E2 enzyme in the same manner as the mutations to the APC11 Ub-binding exosite ( Figure 4F ). The inhibitory effect of Ubv on APC/C function was also observed in a Xenopus egg system ( Table 3 ).
The APC11-binding Ubv was further used in cryo-EM reconstructions to define architectures of Substrate-Ub-APC/C in complex with either UBE2C E2 enzyme involved in multiubiquitination or UBE2S E2 enzyme involved in chain elongation. 65 The use of the high affinity Ubv in place of the low affinity Ub.wt was combined with cross-linking of E2 enzymes to allow visualization of the APC/C complexes that are otherwise too transient to characterize structurally. Cryo-EM structures and biochemical assays revealed that UBE2C and UBE2S E2
enzymes interact with the Substrate-Ub-APC/C complex in a strikingly different manner and provided an explanation for the non-overlapping roles of the two enzymes in multiubiquitination and chain elongation. The APC11-binding Ubv provides yet another example of Ubvs mimicking the interaction of Ub.wt and demonstrates the utility of using high affinity Ubvs for structural studies. While the Ubv was used to help define the architectures of the APC/C complexes, it may also prove useful for exploring the biological consequences of inhibiting the APC11 Ub-binding exosite. Furthermore, given the complexity of the APC/C complex, it would be interesting to explore whether Ubv inhibitors or modulators can be generated against other subunits of the APC/C complex. 21 has been observed in several other studies suggesting that it should be possible to generate Ubv activators of other UPS proteins.
| C O NC LU S I O N S
In conclusion, Ubvs developed against UPS proteins can serve as valuable tools both for basic research and for the development of therapeutic strategies. Several applications have been demonstrated in the described studies, including using high affinity Ubvs in place of Ub.wt for structural and functional studies, using Ubv pools to validate and discover new functions for targets, and using Ubvs to identify and characterize new modulatory sites. Other potential applications such as the use of Ubvs in small molecule displacement screens and therapeutic target validation remain to be explored.
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